92 related articles for article (PubMed ID: 10463682)
1. Short report: evaluation of the potency and stability of a candidate vaccine against American cutaneous leishmaniasis.
Mayrink W; Pinto J; Da Costa C; Toledo V; Guimarães T; Genaro O; Vilela L
Am J Trop Med Hyg; 1999 Aug; 61(2):294-5. PubMed ID: 10463682
[TBL] [Abstract][Full Text] [Related]
2. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.
Vélez ID; Gilchrist K; Arbelaez MP; Rojas CA; Puerta JA; Antunes CM; Zicker F; Modabber F
Trans R Soc Trop Med Hyg; 2005 Aug; 99(8):593-8. PubMed ID: 15893351
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Alves CR; Coutinho SG; Oliveira MP; Bertho AL; Toledo VP; Costa CA; Genaro O; Mendonça SC
Vaccine; 1999 Mar; 17(9-10):1179-85. PubMed ID: 10195630
[TBL] [Abstract][Full Text] [Related]
4. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.
Sharifi I; FeKri AR; Aflatonian MR; Khamesipour A; Nadim A; Mousavi MR; Momeni AZ; Dowlati Y; Godal T; Zicker F; Smith PG; Modabber F
Lancet; 1998 May; 351(9115):1540-3. PubMed ID: 10326536
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind placebo-controlled trial to evaluate the immunogenicity of a candidate vaccine against American tegumentary leishmaniasis.
De Luca PM; Mayrink W; Pinto JA; Coutinho SG; Santiago MA; Toledo VP; Costa CA; Genaro O; Reis AB; Mendonça SC
Acta Trop; 2001 Dec; 80(3):251-60. PubMed ID: 11700183
[TBL] [Abstract][Full Text] [Related]
6. Immune response measured in human volunteers vaccinated with autoclaved Leishmania major vaccine mixed with low dose of BCG.
Mahmoodi M; Khamesipour A; Dowlati Y; Rafati S; Momeni AZ; Emamjomeh M; Hejazi H; Modabber F
Clin Exp Immunol; 2003 Nov; 134(2):303-8. PubMed ID: 14616791
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 study of an inactivated vaccine against American tegumentary leishmaniasis in normal volunteers in Brazil.
Marzochi KB; Marzochi MA; Silva AF; Grativol N; Duarte R; Confort EM; Modabber F
Mem Inst Oswaldo Cruz; 1998; 93(2):205-12. PubMed ID: 9698895
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.
Armijos RX; Weigel MM; Calvopina M; Hidalgo A; Cevallos W; Correa J
Vaccine; 2004 Mar; 22(9-10):1320-6. PubMed ID: 15003662
[TBL] [Abstract][Full Text] [Related]
9. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran.
Momeni AZ; Jalayer T; Emamjomeh M; Khamesipour A; Zicker F; Ghassemi RL; Dowlati Y; Sharifi I; Aminjavaheri M; Shafiei A; Alimohammadian MH; Hashemi-Fesharki R; Nasseri K; Godal T; Smith PG; Modabber F
Vaccine; 1999 Feb; 17(5):466-72. PubMed ID: 10073725
[TBL] [Abstract][Full Text] [Related]
10. Safety and immunogenicity of a killed Leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: a randomized controlled trial.
Vélez ID; del Pilar Agudelo S; Arbelaez MP; Gilchrist K; Robledo SM; Puerta JA; Zicker F; Berman J; Modabber F
Trans R Soc Trop Med Hyg; 2000; 94(6):698-703. PubMed ID: 11198661
[TBL] [Abstract][Full Text] [Related]
11. The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis.
Alimohammadian MH; Khamesipour A; Darabi H; Firooz A; Malekzadeh S; Bahonar A; Dowlati Y; Modabber F
Vaccine; 2002 Dec; 21(3-4):174-80. PubMed ID: 12450691
[TBL] [Abstract][Full Text] [Related]
12. Comparative evaluation of phenol and thimerosal as preservatives for a candidate vaccine against American cutaneous leishmaniasis.
Mayrink W; Tavares CA; Deus RB; Pinheiro MB; Guimarães TM; Andrade HM; Costa CA; Toledo Vde P
Mem Inst Oswaldo Cruz; 2010 Feb; 105(1):86-91. PubMed ID: 20209335
[TBL] [Abstract][Full Text] [Related]
13. Randomized, double-blind, placebo-controlled study on the immunogenicity of the leishmanin skin test.
De Luca PM; Mayrink W; Santiago MA; Nogueira R; Conceição-Silva F; Mélo G; Mendonça SC
Trans R Soc Trop Med Hyg; 2003; 97(6):709-12. PubMed ID: 16117969
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (Alum-precipitated autoclaved Leishmania major + BCG) in children: an extended phase II study.
Khalil EA; Musa AM; Modabber F; El-Hassan AM
Ann Trop Paediatr; 2006 Dec; 26(4):357-61. PubMed ID: 17132302
[TBL] [Abstract][Full Text] [Related]
15. Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis.
Kenney RT; Sacks DL; Sypek JP; Vilela L; Gam AA; Evans-Davis K
J Immunol; 1999 Oct; 163(8):4481-8. PubMed ID: 10510390
[TBL] [Abstract][Full Text] [Related]
16. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
[TBL] [Abstract][Full Text] [Related]
17. The role of TLR9 on Leishmania amazonensis infection and its influence on intranasal LaAg vaccine efficacy.
Pratti JES; da Fonseca Martins AM; da Silva JP; Ramos TD; Pereira JC; Firmino-Cruz L; Oliveira-Maciel D; Vieira TSS; Lacerda LL; Vale AM; Freire-de-Lima CG; Gomes DCO; Saraiva EM; Rossi-Bergmann B; de Matos Guedes HL
PLoS Negl Trop Dis; 2019 Feb; 13(2):e0007146. PubMed ID: 30802247
[TBL] [Abstract][Full Text] [Related]
18. Characterization of human T lymphocyte-mediated immune responses induced by a vaccine against American tegumentary leishmaniasis.
Mendonca SC; De Luca PM; Mayrink W; Restom TG; Conceicao-Silva F; Da-Cruz AM; Bertho AL; Da Costa CA; Genaro O; Toledo VP
Am J Trop Med Hyg; 1995 Aug; 53(2):195-201. PubMed ID: 7677224
[TBL] [Abstract][Full Text] [Related]
19. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up.
Armijos RX; Weigel MM; Aviles H; Maldonado R; Racines J
J Infect Dis; 1998 May; 177(5):1352-7. PubMed ID: 9593024
[TBL] [Abstract][Full Text] [Related]
20. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
Rafati S; Ghaemimanesh F; Zahedifard F
Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
